Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 74 articles: HTML format Text format

Single Articles

November 2018
1. FOIDART P, Yip C, Radermacher J, Lienard M, et al
   Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy.
   Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-1880.
   PubMed     Text format     Abstract available
   
   
   
2. SHIINO S, Matsuzaki J, Shimomura A, Kawauchi J, et al
   Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer.
   Clin Cancer Res. 2018 Nov 27. pii: 1078-0432.CCR-18-1414.
   PubMed     Text format     Abstract available
   
   
   
3. RACHNER TD, Kasimir-Bauer S, Gobel A, Erdmann K, et al
   Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in non-metastatic breast cancer.
   Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2482.
   PubMed     Text format     Abstract available
   
   
   
4. 
   Correction: Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
   Clin Cancer Res. 2018;24:5486.
   PubMed     Text format    
   
   
   
5. 
   Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.
   Clin Cancer Res. 2018;24:5485.
   PubMed     Text format    
   
   
   October 2018
6. WANG Z, Liu Q, Wilson CL, Easton J, et al
   Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE).
   Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1775.
   PubMed     Text format     Abstract available
   
   
   
7. GRELLETY T, Callens C, Richard E, Briaux A, et al
   Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target.
   Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1469.
   PubMed     Text format     Abstract available
   
   
   
8. VELDWIJK MR, Seibold P, Botma A, Helmbold I, et al
   Association of CD4(+) radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with >10-year follow-up.
   Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-0777.
   PubMed     Text format     Abstract available
   
   
   
9. CROESSMANN S, Formisano L, Kinch L, Gonzalez-Ericsson PI, et al
   Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
   Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-1544.
   PubMed     Text format     Abstract available
   
   
   
10. ABOUTALIB SS, Mohamed AA, Berg WA, Zuley ML, et al
    Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening.
    Clin Cancer Res. 2018 Oct 11. pii: 1078-0432.CCR-18-1115.
    PubMed     Text format     Abstract available
    
    
    September 2018
11. THOREK DL, Ku AT, Mitsiades N, Veach D, et al
    Harnessing Androgen-Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
    Clin Cancer Res. 2018 Sep 25. pii: 1078-0432.CCR-18-1521.
    PubMed     Text format     Abstract available
    
    
    
12. HENDERSON MC, Silver M, Tran Q, Letsios EE, et al
    A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0843.
    PubMed     Text format     Abstract available
    
    
    
13. CHEN X, Low KH, Alexander A, Jiang Y, et al
    Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1446.
    PubMed     Text format     Abstract available
    
    
    August 2018
14. GUINDALINI RS, Zheng Y, Abe H, Whitaker K, et al
    Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
    Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-0200.
    PubMed     Text format     Abstract available
    
    
    
15. MEIJER TG, Verkaik NS, Sieuwerts AM, van Riet J, et al
    Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0063.
    PubMed     Text format     Abstract available
    
    
    
16. MENDEZ O, Peg V, Salvans C, Pujals M, et al
    Extracellular HMGA1 promotes tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Aug 22. pii: 1078-0432.CCR-18-0517.
    PubMed     Text format     Abstract available
    
    
    
17. TRAN TH, Utama FE, Sato T, Peck AR, et al
    Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-17-3280.
    PubMed     Text format     Abstract available
    
    
    
18. CHEUNG A, Opzoomer JW, Ilieva KM, Gazinska P, et al
    Anti-Folate Receptor alpha-directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0652.
    PubMed     Text format     Abstract available
    
    
    July 2018
19. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Khan QJ, et al
    Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0585.
    PubMed     Text format     Abstract available
    
    
    
20. TANIOKA M, Fan C, Parker JS, Hoadley KA, et al
    Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-17-3431.
    PubMed     Text format     Abstract available
    
    
    
21. GONZALEZ-GONZALEZ A, Munoz-Muela E, Marchal JA, Cara FE, et al
    Activating transcription factor 4 modulates TGFbeta-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3125.
    PubMed     Text format     Abstract available
    
    
    June 2018
22. SHEN H, Mu C, Wu X, Zhou X, et al
    Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-17-3872.
    PubMed     Text format     Abstract available
    
    
    
23. CUI Y, Li B, Pollom EL, Horst K, et al
    Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0825.
    PubMed     Text format     Abstract available
    
    
    
24. PARK H, Lim Y, Ko ES, Cho HH, et al
    Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer.
    Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-3783.
    PubMed     Text format     Abstract available
    
    
    
25. SHAH D, Wyatt D, Baker A, Simms P, et al
    Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1.
    Clin Cancer Res. 2018 Jun 12. pii: 1078-0432.CCR-17-1952.
    PubMed     Text format     Abstract available
    
    
    
26. BARRY P, Vatsiou A, Spiteri I, Nichol D, et al
    The spatio-temporal evolution of lymph node spread in early breast cancer.
    Clin Cancer Res. 2018 Jun 11. pii: 1078-0432.CCR-17-3374.
    PubMed     Text format     Abstract available
    
    
    
27. BARDIA A, Hurvitz S
    Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.
    Clin Cancer Res. 2018 Jun 8. pii: 1078-0432.CCR-18-0162.
    PubMed     Text format     Abstract available
    
    
    May 2018
28. UNNI N, Sudhan DR, Arteaga CL
    Neratinib: Inching up on the cure rate of HER2+ breast cancer?
    Clin Cancer Res. 2018 May 25. pii: 1078-0432.CCR-18-1114.
    PubMed     Text format     Abstract available
    
    
    
29. ANURAG M, Punturi N, Hoog J, Bainbridge MN, et al
    Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-17-3702.
    PubMed     Text format     Abstract available
    
    
    
30. DICKLER MN, Saura C, Richards D, Krop I, et al
    Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-18-0613.
    PubMed     Text format     Abstract available
    
    
    
31. BAYRAKTAR R, Ivan C, Bayraktar E, Kanlikilicer P, et al
    Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-17-1959.
    PubMed     Text format     Abstract available
    
    
    April 2018
32. SPRING L, Bardia A
    Cycling Towards Progress: Ribociclib, CDK 4/6 inhibitor for Breast Cancer.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0463.
    PubMed     Text format     Abstract available
    
    
    
33. VISSER LL, Elshof LE, Schaapveld M, Van de Vijver K, et al
    Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ - A nested case-control study.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0201.
    PubMed     Text format     Abstract available
    
    
    
34. GOODMAN CR, Seagle BL, Kocherginsky M, Donnelly ED, et al
    21-gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1-2 N1 breast cancer.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3169.
    PubMed     Text format     Abstract available
    
    
    
35. POST AEM, Smid M, Nagelkerke A, Martens JWM, et al
    Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-2551.
    PubMed     Text format     Abstract available
    
    
    
36. WEST DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, et al
    Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2793.
    PubMed     Text format     Abstract available
    
    
    
37. LOIBL S, Weber K, Huober J, Krappmann K, et al
    Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-2947.
    PubMed     Text format     Abstract available
    
    
    
38. RUGO HS, Cortes J, Awada A, O'Shaughnessey J, et al
    Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3059.
    PubMed     Text format     Abstract available
    
    
    March 2018
39. AFGHAHI A, Purington N, Han SS, Desai M, et al
    Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Mar 26. pii: 1078-0432.CCR-17-1323.
    PubMed     Text format     Abstract available
    
    
    
40. WARD E, Vareslija D, Charmsaz S, Fagan A, et al
    Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
    Clin Cancer Res. 2018 Mar 22. pii: 1078-0432.CCR-17-2615.
    PubMed     Text format     Abstract available
    
    
    
41. RUGO HS, Delord JP, Im SA, Ott PA, et al
    Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen ReceptorPositive/Human Epidermal Growth Factor Receptor 2Negative Advanced Breast Cancer.
    Clin Cancer Res. 2018 Mar 20. pii: 1078-0432.CCR-17-3452.
    PubMed     Text format     Abstract available
    
    
    
42. CHUMSRI S, Sperinde J, Liu H, Gligorov J, et al
    High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-1864.
    PubMed     Text format     Abstract available
    
    
    
43. FILIPITS M, Dafni U, Gnant M, Polydoropoulou V, et al
    Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3473.
    PubMed     Text format     Abstract available
    
    
    
44. SINGH H, Walker AJ, Amiri-Kordestani L, Cheng J, et al
    U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.
    Clin Cancer Res. 2018 Mar 9. pii: 1078-0432.CCR-17-3628.
    PubMed     Text format     Abstract available
    
    
    
45. RICCIARDELLI C, Bianco-Miotto T, Jindal S, Butler LM, et al
    The Magnitude of Androgen Receptor Positivity in Breast Cancer is Critical for Reliable Prediction of Disease Outcome.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-1199.
    PubMed     Text format     Abstract available
    
    
    
46. LIU L, Yang L, Yan W, Zhai J, et al
    Chemotherapy induces breast cancer stemness in association with dysregulated monocytosis.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-2545.
    PubMed     Text format     Abstract available
    
    
    February 2018
47. FORMENTI SC, Lee P, Adams S, Goldberg JD, et al
    Focal Irradiation And Systemic Transforming Growth Factor beta Blockade in Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-3322.
    PubMed     Text format     Abstract available
    
    
    
48. NEVEN P, Jongen L, Lintermans A, Van Asten K, et al
    Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial.
    Clin Cancer Res. 2018 Feb 19. pii: 1078-0432.CCR-17-3028.
    PubMed     Text format     Abstract available
    
    
    
49. KARAPANAGIOTIS S, Pharoah PDP, Jackson CH, Newcombe PJ, et al
    Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-3542.
    PubMed     Text format     Abstract available
    
    
    
50. HAMILTON EP, Patel MR, Armstrong AC, Baird RD, et al
    A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-17-3102.
    PubMed     Text format     Abstract available
    
    
    
51. SHAH A, Bloomquist E, Tang S, Fu W, et al
    FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
    PubMed     Text format     Abstract available
    
    
    
52. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Text format     Abstract available
    
    
    
53. MARTINS CD, Da Pieve C, Burley TA, Smith R, et al
    HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2754.
    PubMed     Text format     Abstract available
    
    
    
54. GONG C, Man EP, Tsoi H, Lee TK, et al
    BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer.
    Clin Cancer Res. 2018 Feb 2. pii: 1078-0432.CCR-17-2259.
    PubMed     Text format     Abstract available
    
    
    January 2018
55. MISHRA RR, Belder N, Ansari SA, Kayhan M, et al
    Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer.
    Clin Cancer Res. 2018 Jan 31. pii: 1078-0432.CCR-17-2776.
    PubMed     Text format     Abstract available
    
    
    
56. ECHAVARRIA I, Lopez-Tarruella S, Picornell AC, Garcia-Saenz JA, et al
    Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    Clin Cancer Res. 2018 Jan 29. pii: 1078-0432.CCR-17-1912.
    PubMed     Text format     Abstract available
    
    
    
57. PIGGOTT L, da Silva AM, Robinson T, Santiago-Gomez A, et al
    Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
    Clin Cancer Res. 2018 Jan 23. pii: 1078-0432.CCR-17-1381.
    PubMed     Text format     Abstract available
    
    
    
58. YANG X, Pan Y, Qiu Z, Du Z, et al
    RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
    Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
    PubMed     Text format     Abstract available
    
    
    
59. MAGBANUA MJM, Rugo HS, Wolfe DM, Hauranieh L, et al
    Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2312.
    PubMed     Text format     Abstract available
    
    
    
60. DAVILA-GONZALEZ D, Choi DS, Rosato RR, Granados-Principal S, et al
    Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1437.
    PubMed     Text format     Abstract available
    
    
    December 2017
61. MASTORAKI S, Strati A, Tzanikou E, Chimonidou M, et al
    ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
    Clin Cancer Res. 2017 Dec 28. pii: 1078-0432.CCR-17-1181.
    PubMed     Text format     Abstract available
    
    
    
62. ZHAO EY, Shen Y, Pleasance E, Kasaian K, et al
    Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Clin Cancer Res. 2017;23:7521-7530.
    PubMed     Text format     Abstract available
    
    
    November 2017
63. LENZ G, Hamilton A, Geng S, Hong T, et al
    t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
    PubMed     Text format     Abstract available
    
    
    
64. ROSSI G, Mu Z, Rademaker A, Austin L, et al
    Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
    PubMed     Text format     Abstract available
    
    
    
65. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    PubMed     Text format     Abstract available
    
    
    
66. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
    A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Clin Cancer Res. 2017;23:6468-6477.
    PubMed     Text format     Abstract available
    
    
    October 2017
67. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
    Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
    Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
    PubMed     Text format     Abstract available
    
    
    
68. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Text format     Abstract available
    
    
    
69. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
70. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    PubMed     Text format     Abstract available
    
    
    
71. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    PubMed     Text format     Abstract available
    
    
    
72. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
    Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
    Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
    PubMed     Text format     Abstract available
    
    
    
73. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
    A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
    PubMed     Text format     Abstract available
    
    
    
74. DIOT G, Metz S, Noske A, Liapis E, et al
    Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: